ProShare Advisors LLC Grows Stock Holdings in Evolus, Inc. (NASDAQ:EOLS)

ProShare Advisors LLC raised its position in shares of Evolus, Inc. (NASDAQ:EOLS) by 31.0% in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 18,563 shares of the company’s stock after buying an additional 4,392 shares during the period. ProShare Advisors LLC’s holdings in Evolus were worth $205,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also modified their holdings of the company. Nantahala Capital Management LLC boosted its holdings in Evolus by 10.8% in the fourth quarter. Nantahala Capital Management LLC now owns 3,130,149 shares of the company’s stock valued at $34,557,000 after purchasing an additional 305,300 shares during the period. Caligan Partners LP boosted its holdings in Evolus by 22.7% in the fourth quarter. Caligan Partners LP now owns 2,692,388 shares of the company’s stock valued at $29,724,000 after purchasing an additional 498,900 shares during the period. Millennium Management LLC boosted its holdings in Evolus by 29.1% in the fourth quarter. Millennium Management LLC now owns 1,368,423 shares of the company’s stock valued at $15,107,000 after purchasing an additional 308,753 shares during the period. Boothbay Fund Management LLC boosted its holdings in Evolus by 30.9% in the fourth quarter. Boothbay Fund Management LLC now owns 1,287,767 shares of the company’s stock valued at $14,217,000 after purchasing an additional 304,065 shares during the period. Finally, Geode Capital Management LLC boosted its holdings in Evolus by 0.3% in the fourth quarter. Geode Capital Management LLC now owns 1,214,590 shares of the company’s stock valued at $13,412,000 after purchasing an additional 3,969 shares during the period. 90.69% of the stock is currently owned by hedge funds and other institutional investors.

Evolus Trading Up 0.3%

EOLS opened at $9.37 on Monday. Evolus, Inc. has a 52 week low of $8.67 and a 52 week high of $17.82. The company has a quick ratio of 2.23, a current ratio of 2.47 and a debt-to-equity ratio of 20.58. The firm has a market cap of $604.14 million, a price-to-earnings ratio of -10.30 and a beta of 1.11. The business’s 50 day moving average is $10.61 and its two-hundred day moving average is $11.97.

Insider Buying and Selling

In other news, CFO Sandra Beaver sold 6,494 shares of Evolus stock in a transaction dated Tuesday, May 13th. The shares were sold at an average price of $10.02, for a total value of $65,069.88. Following the sale, the chief financial officer now owns 167,089 shares of the company’s stock, valued at $1,674,231.78. The trade was a 3.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CMO Tomoko Yamagishi-Dressler sold 4,536 shares of the stock in a transaction dated Tuesday, March 18th. The stock was sold at an average price of $13.26, for a total transaction of $60,147.36. Following the transaction, the chief marketing officer now directly owns 95,671 shares of the company’s stock, valued at $1,268,597.46. This represents a 4.53% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 86,241 shares of company stock valued at $1,048,666 over the last quarter. 6.10% of the stock is currently owned by insiders.

Wall Street Analyst Weigh In

EOLS has been the subject of a number of recent research reports. Needham & Company LLC reiterated a “buy” rating and issued a $22.00 target price on shares of Evolus in a report on Thursday, May 8th. Barclays raised their price target on Evolus from $22.00 to $25.00 and gave the company an “overweight” rating in a research note on Wednesday, March 5th. BTIG Research initiated coverage on Evolus in a research note on Thursday, April 17th. They issued a “buy” rating and a $21.00 price target on the stock. Finally, HC Wainwright restated a “buy” rating and issued a $27.00 price target on shares of Evolus in a research note on Thursday, April 10th. Five analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $23.75.

Evolus Profile

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.